2016-2021 Associate Retina-Vitreous Associates of Florida, Clearwater, FL.
EDUCATION AND TRAINING
2014-2016 Louisiana State University Health Sciences CenterNew Orleans, LA Fellowship, Vitreoretinal Surgery
2013-2014 University of South Florida Morsani College of Medicine Tampa, FL Chief Resident, Department of Ophthalmology
2011-2014 University of South Florida Morsani College of Medicine Tampa, FL Residency, Department of Ophthalmology
2010-2011 Emory University School of Medicine Atlanta, GA Transitional Year Internship, Department of Internal Medicine
2006-2010 Emory University School of Medicine Atlanta, GA Doctor of Medicine
2001-2005 Duke University Durham, NC Bachelor of Science in Engineering Major: Biomedical Engineering Minor: Chemistry
2016 - 2026 Certification: American Board of Ophthalmology
Dean’s Scholarship 2006
Atlanta Medical Association Scholarship 2006
National Dean’s List 2005
National Merit Semifinalist 2001
National Achievement Scholarship 2001
National Urban League Scholarship 2001
Top 10 Student, School District of Hillsborough County 2001
2016-2021 Tampa Bay Ophthalmic Society
2011-2021 American Academy of Ophthalmology
Largo Medical Center,
Armenia Surgery Cente
2016-2021 Ophthotech Protocol OPH1004A: A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination with Either Avastin or Eylea Monotherapy in Subjects with Neovascular Age-Related Macular Degeneration, Investigator.
2016-2021 Thrombogenics Protocol TG-MV-018: Ocriplasmin Research to Better Inform Treatment (ORBIT) Phase 4 Trial, Investigator.
2016-2021 Genentech/Roche Protocol GX29185: A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration, Investigator.
Margo CE, White AA Jr. Ocular Surface Squamous Neoplasia.Terminology that is Conceptually Friendly but Clinically Perilous. Eye (Lond). 2014 May;28(5):507-9
White AA Jr, Saunders TS, Pavan PR. 26 year-old man with a blind spot in his left eye. Digital Journal of Ophthalmology. 2013 Sep 25;19(3):46-9
Randleman JB, White AJ Jr, Lynn MJ, Hu MH, Stulting RD. Incidence, outcomes, and risk factors for retreatment after wavefront-optimized ablations with PRK and LASIK. J Refract Surg. 2009 Mar; 25(3):273-6
Randleman JB, Perez-Straziota CE, Hu MH, White AJ, Loft ES, Stuliting RD. Higher-order aberrations after wavefront-optimized photorefractive keratectomy and laser in situ keratomileusis. Journal of Cataract & Refractive Surgery. 2009 Feb; 35(2): 260-264.
PRESENTATIONS AND PUBLISHED ABSTRACTS
2015 ARVO Annual MeetingDenver, CO Poster Presentation: Postoperative outcomes in attending versus fellow-performed macular hole surgery
2014 ASCRS Symposium on Cataract, IOL, and Refractive Surgery Boston,MA Oral Presentation: Effect of angle kappa correction on outcomes following hyperopic refractive surgery
2008 ASCRS Symposium on Cataract, IOL, and Refractive Surgery Chicago, IL Oral Presentation: Incidence and Risk Factors for Enhancement after Wavefront-Optimized Advanced Surface Ablation and LASIK
2008 ARVO Annual Meeting Ft. Lauderdale, FL Poster Presentation: Incidence and Risk Factors for Enhancement after Wavefront-Optimized Advanced Surface Ablation and LASIK
2016-2017 Tampa Bay Ophthalmological Society, Secretary
2008-2009 Student Sight Savers/Ophthalmology Interest Group, Chapter President
2007-2008 Physicians in Leadership and Enterprise, Chapter Co-Founder & President
2007-2008 Student Sight Savers/Ophthalmology Interest Group,Chapter Vice-President
2006-2007 Health Professions Recruitment and Exposure Program/SNMA, Chapter Coordinator